izpis_h1_title_alt

A dual biomarker TK1 protein and CA125 or HE4-based algorithm as a better diagnostic tool than ROMA Index in early detection of ovarian cancer
ID Cviič, Diana (Avtor), ID Jagarlamudi, K. K. (Avtor), ID Meglič, Leon (Avtor), ID Škof, Erik (Avtor), ID Zore, Andrej (Avtor), ID Lukanovič, David (Avtor), ID Eriksson, Staffan (Avtor), ID Osredkar, Joško (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (3,69 MB)
MD5: 115C4641B76C0BBEDA11E046033B9D9D
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2072-6694/15/5/1593 Povezava se odpre v novem oknu

Izvleček
Background: The early detection of ovarian cancer is presently not effective, and it is crucial to establish biomarkers for the early diagnosis of ovarian cancer to improve the survival of patients. Materials and methods: The aim of this study was to investigate the role of thymidine kinase 1 (TK1) in combination with CA 125 or HE4 to serve as a potential diagnostic biomarkers for ovarian cancer. In this study, a set of 198 serum samples consisting of 134 ovarian tumor patients and 64 healthy age-matched controls were analyzed. The TK1 protein levels in serum samples were determined using the AroCell TK 210 ELISA. Results: A combination of TK1 protein with CA 125 or HE4 showed better performance than either of them alone in the differentiation of early stage ovarian cancer from the healthy control group, but also a significantly better performance than the ROMA index. However, this was not observed using a TK1 activity test in combination with the other markers. Furthermore, the combination of TK1 protein and CA 125 or HE4 could differentiate early stage disease (stage I, II) more efficiently from advanced-stage (stage III, IV) disease (p < 0.0001). Conclusions: The combination of TK1 protein with CA 125 or HE4 increased the potential of detecting ovarian cancer at early stages.

Jezik:Angleški jezik
Ključne besede:thymidine kinase 1, TK 210 ELISA, TK-liaison, CA 125, HE4, ROMA index, ovarian cancer
Vrsta gradiva:Članek v reviji
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:FFA - Fakulteta za farmacijo
MF - Medicinska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2023
Št. strani:18 str.
Številčenje:Vol. 15, iss. 5, art. 1593
PID:20.500.12556/RUL-144644 Povezava se odpre v novem oknu
UDK:612.621:616-006
ISSN pri članku:2072-6694
DOI:10.3390/cancers15051593 Povezava se odpre v novem oknu
COBISS.SI-ID:144061955 Povezava se odpre v novem oknu
Datum objave v RUL:06.03.2023
Število ogledov:714
Število prenosov:124
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:Cancers
Skrajšan naslov:Cancers
Založnik:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:timidin kinaza 1, indeks ROMA

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj